Patients with myasthenia gravis experience higher comorbidity rates and healthcare utilization compared to healthy controls, indicating a significant disease burden. Treatment patterns for myasthenia ...

Efgartigimod significantly reduced immunoglobulin use, with 95% reduction in annual courses and 84-97% of patients stopping use post-initiation. Hospitalizations, exacerbations, and crisis events ...

Women benefit from planning before conception ...

SAVANNAH, Ga. -- Investigational nipocalimab plus standard of care achieved sustained reductions in immunoglobulin G (IgG) and appeared to be safe for adolescent patients with generalized myasthenia ...

Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.

SAVANNAH, GEORGIA — One patient with autoimmune myasthenia gravis (MG) has a niece with the same diagnosis, and at least one of his other close relatives may have it too. Another patient with MG lost ...

A Bionews survey of 311 people living with the disease finds that three emotions explain 63% of all variation in mental ...

(ENXTBR:ARGX) reported positive topline data from its Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis. The study met its primary endpoint, with statistically significant improvement ...

Findings showed nipocalimab plus standard of care (SOC) improved MG-ADL score from baseline by 4.70 points compared with 3.25 points with placebo plus SOC over weeks 22, 23, and 24. The Food and Drug ...

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied About 10% ...

Tennis legend Monica Seles is opening up about her journey with myasthenia gravis, a neuromuscular autoimmune disease she was diagnosed with three years ago. In a recent interview with The Associated ...